International Conference on Creationism

Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases

Retrieved on: 
Tuesday, November 14, 2023
Alzheimer's disease, Disease, SAN, Disorder, Therapy, ALS, CSF, PSP, Biotechnology, Neurological disorder, Reverse-transcriptase inhibitor, IL-6, Patient, Conference, Frontotemporal dementia, Neuroinflammation, Progressive supranuclear palsy, Biomarker, International Conference on Creationism, Cerebrospinal fluid, Tauopathy, Transposable element, AFL, Medical imaging, Pharmaceutical industry

SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, today announced its abstract of interim results from its Phase 2 study of TPN-101 for the treatment of progressive supranuclear palsy (PSP) has been accepted for poster presentation at the hybrid AD/PD™ 2024: 18th International Conference on Alzheimer's and Parkinson's Diseases. The meeting will take place online and in Lisbon, Portugal, from March 5-9, 2024.

Key Points: 
  • In the treatment group receiving 400 mg of TPN-101 once daily for 24 weeks, TPN-101 showed an 18.4% reduction in NfL levels in CSF as compared to placebo.
  • "The lowering of CSF NfL levels seen in this interim analysis provides biomarker evidence of a treatment effect on neurodegeneration.
  • We are excited about the potential of TPN-101 as a much-needed treatment option for patients with PSP.
  • Transposon will present results from the interim analysis in a poster presentation (abstract #433) at AD/PD 2024 entitled: "A Phase 2a Study of TPN-101, a Nucleoside Reverse Transcriptase Inhibitor, in Patients with Progressive Supranuclear Palsy."

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

Retrieved on: 
Friday, June 9, 2023
PTCL, Hodgkin lymphoma, Abstract, Peripheral T-cell lymphoma, ASH, REDIRECT, Affimer, Bacterial conjugation, Lymphoma, Cancer, Food and Drug Administration, NK, International Conference on Creationism, Poster, Patient, Samsung Medical Center, FDA, IND, Nanakaly Hospital for Hematology & Oncology, Conference, Food, Safety, Pharmaceutical industry, Medical imaging, Book

An additional encore oral presentation will show the final results of the phase 2 REDIRECT study with AFM13 monotherapy in a r/r PTCL patient population.

Key Points: 
  • An additional encore oral presentation will show the final results of the phase 2 REDIRECT study with AFM13 monotherapy in a r/r PTCL patient population.
  • Associated with the AFM13-induced cytotoxic activity was an increased functional activation status of AB-101 demonstrated through degranulation and IFN-γ production.
  • Importantly, in a mouse xenograft model, adoptive transfer of AB-101 in combination with AFM13 conferred tumor growth control.
  • The data of AFM13 in combination with the allogeneic, cryopreserved, off-the-shelf, cord blood-derived AB-101 NK cells demonstrate synergistic anti-tumor activity in vivo.

Upstream Bio Presents New Phase 1 Clinical Data on UPB-101 at the American Thoracic Society (ATS) International Conference

Retrieved on: 
Monday, May 22, 2023
Health, Biometrics, Clinical Trials, Research, Pharmaceutical, Science, PK, Male, Asthma, PD, Bio, Serum, SC, ATS, TSLP, DC, Pharmacokinetics, Inflammation, Female, Trial of the century, Research and development, Development, American Thoracic Society, International Conference on Creationism, Patient, Thymic stromal lymphopoietin, Poster, Conference, Safety, Pharmaceutical industry

Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today presented new clinical data from its Phase 1 clinical study of UPB-101, a thymic stromal lymphopoietin receptor (TSLPR) inhibitor, at the American Thoracic Society (ATS) International Conference in Washington, DC.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today presented new clinical data from its Phase 1 clinical study of UPB-101, a thymic stromal lymphopoietin receptor (TSLPR) inhibitor, at the American Thoracic Society (ATS) International Conference in Washington, DC.
  • Data from the poster presentation show that UPB-101 displayed favorable safety and tolerability following single-dose administration in healthy participants.
  • “Continuing the development of UPB-101 in our ongoing Phase 1b trial in patients with asthma and confirming extended dosing intervals is imperative.
  • A PK profile projected to maintain exposure greater than the estimated minimal therapeutic concentration when dosed at 12-week intervals.

aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference

Retrieved on: 
Monday, May 22, 2023
Sarcoidosis, Myelocyte, Inflammation, Macrophage, Small RNA, Neuropilin, ATyr Pharma, ATS, DC, Immunoassay, ILD, IL-6, Tumor necrosis factor, Research, FC, Macrophage inflammatory protein, American Thoracic Society, Biomarker, Monocyte, Vital capacity, International Conference on Creationism, Patient, SAN, Flow cytometry, Pulmonary alveolar proteinosis, Phenotype, Safety, Convention center, Conference, MCP-1, Disease, Medical imaging, Pharmaceutical industry, Fibrosis

SAN DIEGO, May 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2023 International Conference, which is scheduled to take place May 19 – 24 in Washington, DC.

Key Points: 
  • Exposure-efficacy data from Phase 1b/2a study of efzofitimod support efficacy across multiple clinically relevant endpoints in pulmonary sarcoidosis patients.
  • “We present new data showing that by binding to neuropilin-2, efzofitimod modulates immune responses through myeloid cells.
  • By targeting multiple drivers of inflammation, efzofitimod provides a differentiated approach to resolving chronic inflammation.
  • aTyr is currently conducting EFZO-FIT™, a global pivotal Phase 3 study of efzofitimod in pulmonary sarcoidosis.

C2N Diagnostics’ Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer’s Disease in Two Studies Presented at AD/PD 2023

Retrieved on: 
Tuesday, April 4, 2023
Research, Mental Health, Neurology, Clinical Trials, Other Health, Biotechnology, General Health, Health, Science, Other Science, Lund University, University, Diagnosis, APS2, PCP, Alzheimer's disease, DSM-IV codes, University of Wisconsin–Madison, Deficit spending, PET, Brain, Biomarker, Cerebrospinal fluid, Dementia, Plasma, International Conference on Creationism, Patient, Standard of care, Palmquist, Overdiagnosis, AUC, CSF, AD, Conference, Amyloid, BBM, Medical imaging, Medical device

The APS2 results determine whether a patient is positive or negative for brain amyloid plaques based on a binary cutoff value.

Key Points: 
  • The APS2 results determine whether a patient is positive or negative for brain amyloid plaques based on a binary cutoff value.
  • All patients received the PrecivityAD2 blood test as well as cerebrospinal fluid (CSF) analysis or an amyloid positron emission tomography (PET) scan.
  • The blood biomarkers showed robust clinical validity and accuracy among patients with comorbidities known to interfere with the performance of plasma.
  • This means blood biomarkers with prospectively defined endpoints, validation across multiple different independent cohorts, suitability for use in primary care, and the ability to help with both diagnosis and risk prediction.

Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023

Retrieved on: 
Thursday, February 23, 2023
MAF (gene), Primate, Insulin, Pitt, PDX1, University, Cancer, MD, DO, Defence Institute of Advanced Technology, Treatment, International Conference on Creationism, Patient, Pancreas, Pediatric surgery, AAV, Type 1, Conference, Streptozotocin, C-peptide, ATTD, Pharmaceutical industry, Medical device, Diabetes

AUSTIN, Texas, Feb. 23, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that data highlighting the potential of Genprex's gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 2023 in Berlin, Germany. 

Key Points: 
  • The complete presentation will be available on the Company's website here following the close of Dr. Kalsi's presentation.
  • They received a novel infusion process that used an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.
  • "These results are compelling as they demonstrate the potential for this gene therapy to create newly formed beta-like cells that can produce insulin.
  • Importantly, it shows a positive data progression from our earlier mouse model data to these NHP data," noted Dr. Gittes.